BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37837549)

  • 1. GPR37 expression as a prognostic marker in gliomas: a bioinformatics-based analysis.
    Liang K; Guo Z; Zhang S; Chen D; Zou R; Weng Y; Peng C; Xu Z; Zhang J; Liu X; Pang X; Ji Y; Liao D; Lai M; Peng H; Ke Y; Wang Z; Wang Y
    Aging (Albany NY); 2023 Oct; 15(19):10146-10167. PubMed ID: 37837549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.
    Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C
    Front Immunol; 2022; 13():1052692. PubMed ID: 36685506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Liu YJ; Zeng SH; Qian WH; Tao MX; Zhu YY; Li JP
    Pharmgenomics Pers Med; 2022; 15():261-275. PubMed ID: 35370417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma.
    Zou R; Zhong X; Liang K; Zhi C; Chen D; Xu Z; Zhang J; Liao D; Lai M; Weng Y; Peng H; Pang X; Ji Y; Ke Y; Zhang H; Wang Z; Wang Y
    BMC Cancer; 2023 May; 23(1):403. PubMed ID: 37142967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma.
    Zhu J; Lin Q; Zheng H; Rao Y; Ji T
    Front Oncol; 2022; 12():897042. PubMed ID: 36505882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas.
    Wang J; Xu L; Ding Q; Li X; Wang K; Xu S; Liu B
    Front Immunol; 2023; 14():1065062. PubMed ID: 37325664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGIF2 is a potential biomarker for diagnosis and prognosis of glioma.
    Zhang W; Zhang L; Dong H; Peng H
    Front Immunol; 2024; 15():1356833. PubMed ID: 38629068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
    Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
    Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.
    Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J
    Front Immunol; 2023; 14():1338244. PubMed ID: 38250074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
    Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
    J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients.
    Zhu H; Hu X; Feng S; Gu L; Jian Z; Zou N; Xiong X
    Front Immunol; 2022; 13():946692. PubMed ID: 35928818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma.
    Guo Q; Gao X; Li J; Liu Y; Liu J; Yang H; Cui M; Zhang M; Duan L; Ma X
    Sci Rep; 2023 Mar; 13(1):3820. PubMed ID: 36882457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.